Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

Slides:

Advertisements

Similar presentations

What is Pharmacometrics (PM)?

Advertisements

1 Case Studies in Modeling and Simulation Discussion Stella G. Machado, Ph.D. Office of Biostatistics/OTS/CDER/FDA FDA/Industry Workshop, September 2006.

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.

Poster will be available at after September 10 th 2006 ABSTRACT AN2690 is a new novel antifungal being developed for the treatment of onychomycosis.

Pilot and Pharmacokinetic Studies of Solubilized Estradiol Administered Vaginally in a Softgel Capsule James H. Pickar, M.D., F.A.C.O.G.

American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.

Sample size optimization in BA and BE trials using a Bayesian decision theoretic framework Paul Meyvisch – An Vandebosch BAYES London 13 June 2014.

Pediatric Subcommittee of the AIDAC October 29-30, 2003 Topical Immunosuppressants Bindi M. Nikhar, M.D., FAAP Division of Dermatologic and Dental Drug.

Population PK/PD analysis of the bactericidal activity of sutezolid and its major metabolite against intracellular Mtb in whole blood cultures of TB patients.

Stefan Franzén Introduction to clinical trials.

Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.

Approval of Natural Chemopreventive Product. Scope of The Study Preclinical evaluation (In vivo)Preclinical evaluation (In vivo) –Toxicity testing  Acute.

Charge to the Committee Kimberly Struble, Pharm.D. Regulatory Review Officer Division of Antiviral Drug Products.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

1 11/8/00 Pharmacology of Tacrolimus Ointment William Fitzsimmons, Pharm.D. Vice President Drug Development Project Management Fujisawa Healthcare, Inc.

Michael V. Novinski President and Chief Executive Officer July 29, 2008 Eligen ® B12 – Human Clinical Results.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.

Stefan Franzén Introduction to clinical trials.

ArTiMist™ Clinical Trial Results By Mr Calvin Ross Sofitel Wentworth Hotel Sydney 14 April 2008 Eastland Medical Systems Ltd.

Regulatory Experience Employing Extrapolation In Pediatric Drug Development William Rodriguez, M.D. Science Director of Pediatrics Office of Counter-Terrorism.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Clinical Review of Protopic Safety, Potential Risk, and Efficacy Martin M. Okun, M.D., Ph.D. Lisa Mathis, M.D. Division of Dermatologic and Dental Drug.

© 2010 Universitair Ziekenhuis Gent Population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients translated into clinical.

HOW CAN WE TAILOR DRUG DOSES IN EWING’S SARCOMA TO MAXIMISE BENEFIT AND MINIMISE SIDE EFFECTS?

1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.

Remoxy In Vivo Abuse Resistance Studies Ping Ji, PhD Senior Clinical Pharmacologist Office of Clinical Pharmacology Center of Drug Evaluation and Research.

EFFECTS OF DULOXETINE ON THE PHARMACOKINETICS OF NEBIVOLOL IN HEALTHY VOLUNTEERS Corina Briciu 1, Maria Neag 2, Dana Muntean 3, Corina Bocsan 2, Anca Buzoianu.

Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

The effect of fluvoxamine on the pharmacokinetics, and safety of ivabradine in healthy subjects Adina Popa 1, Laurian Vlase 2, Maria Neag 3, Dana Muntean.

PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,

Individual Bioequivalence: Strengths and Weaknesses of the Current Approach: View from the Generic Pharmaceutical Association by MDS Pharma Services FDA.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H.

BACKGROUND OBJECTIVES DESIGN / METHODS DISCUSSION AND CONCLUSIONS The PPK model is well predicted; pediatric anti-Xa exposure of dalteparin is well characterized.

1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

Background Derma-Smoothe/FS ® (Fluocinolone acetonide ) Contains 0.01% fluocinolone acetonide in an oil base solution, Categorized as a low to medium potency.

Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.

1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.

A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.

CS-1 Elidel ® (pimecrolimus) Cream 1% Safety Update Feb, 2005 Thomas Hultsch, MD Senior Medical Director Novartis Pharmaceuticals Corporation Thomas Hultsch,

1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.

1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.

415 PHT Plasma Level – Time Curve

Copyright © 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir.

Effect of Four Different Meal Types on the Population Pharmacokinetics of Single Dose of Rifapentine in Healthy Male Volunteers Simbarashe P. Zvada 1,

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

AP Stat 2007 Free Response. 1. A. Roughly speaking, the standard deviation (s = 2.141) measures a “typical” distance between the individual discoloration.

Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:

Clinicaloptions.com/hepatitis Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus Slideset on: Garg V, van Heeswijk R, Lee JE,

The Stages of a Clinical Trial

Figure 1: Mean comparative midazolam plasma concentration-time plot

Eucrisa™ - Crisaborole

Using extrapolation to support a pediatric investigational plan: an application in liver transplantation development Thomas Dumortier, Martin Fink, Ovidiu.

Hanneke van der Lee, MD, PhD

Yang Liu, Anne Chain, Rebecca Wrishko,

Drug Therapy in Pediatric Patients

Presentation transcript:

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology and Biopharmaceutics

Adult PK Studies In NDA In healthy volunteers (N=12) –single/multiple topical doses of 0.03, 0.1 and 0.3% tacrolimus ointment In patients (N=49, 0.1%; N=35, 0.3%) –single/multiple doses of 0.1 (N=17) & 0.3% ointment (N=4) –single/multiple doses of 0.1% ointment (N=32) –single/multiple doses of 0.3% ointment (N=31)

Adult Studies (0.1% Protopic™ ) Duration of the studies –b.i.d dosing for 13 days PK sampling on Day 1, 4 and 14 –b.i.d dosing for 7 days PK sampling on Day 1 and 7 Range of total BSA treated: 11-60% Number of patients with > 50% BSA treated= 8

Systemic Exposure of 0.1% Protopic™ From PK Studies In Adults Note: With more than 50% of the total BSA treated, all blood samples had detectable levels of tacrolimus NC=not calculable

Clinical Trials With Concentrations  5ng/mL From Random Sampling In Adults

Key Findings From a Study With 0.3% Tacrolimus Ointment In Adults Face and neck lesions in adults (N=7) are more permeable to the lesions on the trunk and limbs (N=6), leading to 4-7 times higher exposure of tacrolimus. A tendency for lower concentrations of tacrolimus on Day 8 (exception: face and neck regions of treatment).

Pediatric PK Studies in NDA In Pediatric Patients (N=20) –single/multiple doses of 0.1% ointment (N=20, ages 6-12)  No PK study conducted in the age range 2-5 years using 0.1% ointment –single/multiple doses of 0.3% ointment (N=8, ages 5-11)

Pediatric Studies (0.1% Protopic™ ) Duration of the study –b.i.d dosing for 13 days Age Range (6-12 years) Range of total BSA treated: 17-83% Number of patients with > 50% BSA treated= 8

Systemic Exposure of 0.1% Protopic™ From PK Studies In Pediatrics NC=not calculable

Key Findings From a Study with 0.3% Tacrolimus Ointment In Pediatrics The younger children (age 5-6 yrs, N=4) tended to have higher systemic exposure of tacrolimus compared to the older children (age 7-11 yrs, N=4) The older children (age 7-11 yrs) tended to have higher systemic exposure on Day 8 as compared to Day 1.

Highest Observed Concentrations in Clinical Trials From Random Sampling (Age 2-6yrs) Note: These concentrations do not necessarily represent the true Cmax

Systemic Absorption of Topical Tacrolimus Compared to Oral Tacrolimus a AUC(0-  )

Conclusions Adults Systemic absorption of tacrolimus in adults, after topical application of 0.1%, is lower than the exposure generated from oral dosing for transplant rejection. Pediatrics An insufficient number of subjects were enrolled in the PK studies to assess the systemic absorption of tacrolimus in pediatric patients below the age of 5 under maximal use conditions. Further work in this target population should be considered.